Clinical Trial

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 16, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-11-11; most recent amendment 2025-09-10.
Trial Details
NCT Number NCT04162353
Lead Sponsor iCell Gene Therapeutics
Collaborators: iCAR Bio Therapeutics Ltd., Peking University Shenzhen Hospital
Conditions Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Plasmacytoid; Lymphoma
Enrollment 12 participants
Start Date 2019-07-01
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-09-16